Latest news
25 items- 13D/GSEC Form SC 13D/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)
- INSIDERSEC Form 4 filed by Violin Jonathan4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
- 13D/GSEC Form SC 13G/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
- SECCatabasis Pharmaceuticals, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Astria Therapeutics, Inc. (0001454789) (Filer)
- PRCatabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus-- Astria Reflects Company's Patient-Focused Mission -- -- Promising Lead Program STAR-0215 is in Preclinical Development to Prevent Attacks in Hereditary Angioedema -- -- Company to Begin Trading Under New Ticker Symbol ATXS on September 9 -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc. ("Astria" or the "Company"). The name Astria originates from the Greek word for star, reflecting the Company's commitment to having patients serve as guiding stars. Astria's mission is to bring hope with life-changing therapies to patients and famili
- ANALYSTWedbush initiated coverage on Catabasis Pharmaceuticals with a new price targetWedbush initiated coverage of Catabasis Pharmaceuticals with a rating of Outperform and set a new price target of $16.00
- ANALYSTCatabasis Pharmaceuticals upgraded by HC Wainwright & Co. with a new price targetHC Wainwright & Co. upgraded Catabasis Pharmaceuticals from Neutral to Buy and set a new price target of $13.00
- SECCatabasis Pharmaceuticals, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
- SECSEC Form S-8 filed by Catabasis Pharmaceuticals, Inc.S-8 - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
- PRCatabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate UpdateCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. "We are focused on advancing the development of our lead program, QLS-215, as a differentiated and potentially the most patient-friendly treatment option for the chronic treatment of patients with hereditary angioedema to prevent attacks," said Jill C. Milne, Ph.D., Chief Executive Officer of Catabasis. "We anticipate that our first clinical trial with QLS-215 could demonstrate clinical proof of concept of its differentiated profile and long antibody half-life. Initial results from this trial are anticipated
- SECSEC Form 10-Q filed by Catabasis Pharmaceuticals, Inc.10-Q - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
- PRCatabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare ConferenceCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET. The session entitled "HAE There- Development Landscape in Hereditary Angioedema (HAE)" will include an overview of the HAE treatment landscape, information about Catabasis's lead program QLS-215, and a Q&A session. A webcast of the presentation will be available at the following link: https://wsw.com/webcast/wedbush39/panel11/2571740, and will also be available in the investors section of the Company's
- 13D/GSEC Form SC 13G/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)SC 13G/A - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
- PRCatabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare ConferenceCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the upcoming virtual Ladenburg Thalmann Healthcare Conference. The presentation will take place on Tuesday, July 13th, 2021 at 12:30pm ET. A webcast of the presentation will be available at the following link: https://wsw.com/webcast/ladenburg7/catb/2378558, and will also be available in the investors section of the Company's website, www.catabasis.com, and will be archived for 30
- SECCatabasis Pharmaceuticals, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
- SECSEC Form 424B5 filed by Catabasis Pharmaceuticals, Inc.424B5 - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
- 13D/GSEC Form SC 13D/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)SC 13D/A - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
- 13D/GSEC Form SC 13D/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)SC 13D/A - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
- 13D/GSEC Form SC 13D filed by Catabasis Pharmaceuticals, Inc.SC 13D - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
- 13D/GSEC Form SC 13G filed by Catabasis Pharmaceuticals, Inc.SC 13G - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
- 13D/GSEC Form SC 13G filed by Catabasis Pharmaceuticals, Inc.SC 13G - CATABASIS PHARMACEUTICALS INC (0001454789) (Subject)
- INSIDERSEC Form 4 filed by Harshbarger Benjamin4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
- SECCatabasis Pharmaceuticals, Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events (Amendment)8-K/A - CATABASIS PHARMACEUTICALS INC (0001454789) (Filer)
- INSIDERSEC Form 4 filed by Komjathy Andrew4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)
- INSIDERSEC Form 4 filed by Nichols Andrew John4 - CATABASIS PHARMACEUTICALS INC (0001454789) (Issuer)